Using a panel of 17 lung cancer cell lines with varying SALL4 expression levels as a preclinical model, we further confirmed that high SALL4 expression lung cancer cells were more sensitive to entinostat treatment. The gene discussed is SALL4; the disease is lung carcinoma.